West Virginia is currently home to 346 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Morgantown, Charleston, Huntington and Wheeling. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement
NCT02810704
Recruiting
PEPPER is a randomized study comparing the three most commonly used anticoagulants in North America in patients who have elected to undergo primary or revision hip or knee joint replacement surgery. The anticoagulants being compared are enteric coated aspirin, low intensity warfarin, and rivaroxaban.
Gender:
All
Ages:
21 years and above
Trial Updated:
10/30/2023
Locations: West Virginia University, Morgantown, West Virginia
Conditions: Pulmonary Embolism, Venous Thrombosis
Register for Updates
Natural Versus Programmed Frozen Embryo Transfer (NatPro)
NCT04551807
Recruiting
NatPro is a two-arm, parallel-group, multi-center, randomized trial in which women undergoing frozen embryo transfer (FET) will be randomized to receive either a modified natural cycle (corpus luteum present) or a programmed cycle (corpus luteum absent).
Gender:
Female
Ages:
Between 18 years and 41 years
Trial Updated:
10/25/2023
Locations: West Virginia University Center for Reproductive Medicine, Morgantown, West Virginia
Conditions: Pregnancy Related, Pre-Eclampsia
Register for Updates
Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
NCT05172024
Recruiting
This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals who will enter the cohort with and without SARS-CoV-2 infection and at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection and with or without Post-Acute Sequelae of COVID-19 (PASC) symptoms will be followed to identify risk factors and occurrence of PASC. This study will be conducted in the United States and subjects will be recruited through inpatien... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: West Virginia University, Morgantown, West Virginia
Conditions: SARS-CoV2 Infection
Register for Updates
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224
Recruiting
To assess: efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistanc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: West Virginia University Cancer Institute, Morgantown, West Virginia
Conditions: Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, Solid Tumors, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Register for Updates
Treatment of Elevated Blood Pressures in Early Pregnancy
NCT05955040
Recruiting
This is a randomized controlled trial comparing the outcomes of treatment and non-treatment of elevated blood pressures in early pregnancy.
Gender:
Female
Ages:
Between 18 years and 45 years
Trial Updated:
10/17/2023
Locations: Marshall Obstetrics and Gynecology, Huntington, West Virginia
Conditions: Elevated Blood Pressure, Pregnancy Induced Hypertension
Register for Updates
Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids
NCT06047834
Recruiting
A randomized, open-label, controlled, ascending dose cohort, PK, and safety study assessing standard of care (i.e., non-pharmacologic measures and morphine when indicated) with or without lofexidine for the treatment of opioid withdrawal symptoms in neonates due to intrauterine exposure to opioids, described as neonatal opioid withdrawal syndrome (NOWS) or neonatal abstinence syndrome (NAS). This study has been designed to assess the pharmacokinetics (PK) and safety of the lofexidine in neonate... Read More
Gender:
All
Ages:
Between 0 hours and 6 days
Trial Updated:
10/16/2023
Locations: Marshall Health, Huntington, West Virginia
Conditions: Opioid Withdrawal (Disorder)
Register for Updates
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Rheumatoid Arthritis (RENOIR)
NCT06041269
Recruiting
RENOIR Study: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe Rheumatoid Arthritis (RA)
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
10/11/2023
Locations: Anaptys Bio Investigative Site 10-117, Beckley, West Virginia
Conditions: Rheumatoid Arthritis
Register for Updates
Citadel Embolization Device Study
NCT04057352
Recruiting
The purpose of this study is to gather safety and effectiveness data on Stryker Neurovascular's Next Generation Target Detachable Coil (hereafter referred to as the Citadel Embolization Device), when used with Target Detachable Coils, in the treatment of wide-neck intracranial aneurysms.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
09/29/2023
Locations: West Virginia University Hospital, Morgantown, West Virginia
Conditions: Unruptured Wide-neck Aneurysms
Register for Updates
I Vaccinate: Testing Multi-Level Interventions to Improve HPV Vaccination
NCT04452526
Recruiting
This trial studies how well a multi-level health system-based intervention works in improving human papillomavirus (HPV) vaccine initiation and completion among children in health systems in four Appalachian states. Utilizing educational and promotional materials and electronic health record reminders, may improve the uptake of the HPV vaccine in children and young adults, ultimately preventing the development of cervical cancer.
Gender:
All
Ages:
11 years and above
Trial Updated:
09/27/2023
Locations: West Virginia University, Morgantown, West Virginia
Conditions: Cervical Carcinoma, Human Papillomavirus-Related Malignant Neoplasm
Register for Updates
Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study
NCT03911739
Recruiting
This is a sub-study of NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs; Unique protocol ID: 2019-0429-1). Caretakers of the infants delivered by MOMs participants will be offered the opportunity to enroll in this sub-study, which is designed to evaluate the impact of extended-release buprenorphine (BUP-XR), relative to sublingual buprenorphine (BUP-SL), on infant neurodevelopment. The additional data collected in this sub-study will be combined wit... Read More
Gender:
All
Ages:
All
Trial Updated:
09/25/2023
Locations: Marshall Health MARC Program, Huntington, West Virginia
Conditions: Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome, Drug Abuse in Pregnancy
Register for Updates
OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
NCT03747458
Recruiting
This is a 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. The total planned number of subjects is approximately 120 adolescents (12-17 years of age) who will be randomly assigned to receive 1 of 2 study treatments using a 2:1 ratio (OPN-375 186 μg: Placebo). For the PK sub-study, up to 14 subjec... Read More
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
09/22/2023
Locations: West Virginia University, Morgantown, West Virginia
Conditions: Bilateral Nasal Polyposis
Register for Updates
Abatacept in Immune Checkpoint Inhibitor Myocarditis
NCT05335928
Recruiting
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/06/2023
Locations: University of West Virginia, Morgantown, West Virginia
Conditions: Myocarditis Acute, Cancer
Register for Updates